Role of Endothelin-1 Modulating Insulin-stimulated Blood Flow and Sympathetic Nervous System Activity in Obesity

Early Phase 1WithdrawnNCT05518422

University of Missouri-Columbia

Overview

The aim of this project is to determine role for ET-1 in individuals with obesity.

Study Type

INTERVENTIONAL

Allocation

Purpose

BASIC_SCIENCE

Masking

NONE

Conditions

Insulin Resistance Autonomic Dysfunction Obesity

Interventions

Hyperinsulinemic, euglycemic infusionDRUG

60 minute infusion

Eligibility

Sex: MALEMin age: 18 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * 18-55 years of age * Male sex * Obese (BMI ≥30 kg/m2) Exclusion Criteria: * Female sex * Current smoking/Nicotine use * Nerve/neurologic disease * Cardiovascular, hepatic, renal, respiratory disease * Blood pressure ≥140/90 mmHg * Diabetes * Vigorous exercise \>3 times/week * Communication barriers * taking any medications known to affect metabolic, respiratory, cardiovascular, and/or autonomic

Outcomes

Primary Outcomes

Amount of muscle sympathetic nerve activity (MSNA)

MSNA burst incidence (bursts/100 heart beats)

Time frame: Change from baseline at minute 60

Amount of leg blood flow

Measured with Doppler ultrasound (mL/min)

Time frame: Change from baseline at minute 60

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.